Value of Carbon-Ion Radiation Therapy for Breast Cancer.

IF 2.1 Q3 ONCOLOGY International Journal of Particle Therapy Pub Date : 2024-08-30 eCollection Date: 2024-12-01 DOI:10.1016/j.ijpt.2024.100629
Bowen Yu, Kai-Wen Li, Yingyi Fan, Xiaohua Pei
{"title":"Value of Carbon-Ion Radiation Therapy for Breast Cancer.","authors":"Bowen Yu, Kai-Wen Li, Yingyi Fan, Xiaohua Pei","doi":"10.1016/j.ijpt.2024.100629","DOIUrl":null,"url":null,"abstract":"<p><p>To explore the challenges and future of carbon-ion radiation therapy (CIRT) in breast cancer, we summarized the progress of nonclinical and clinical studies on CIRT for breast cancer in this review. A total of 6 nonclinical studies have been reported, which demonstrated a better effect of Carbon-ion irradiation compared with X-ray in breast cancer cell lines (including triple-negative breast cancer and Human Epidermal Growth Factor Receptor 2-negative breast cancer). Combination with Hh inhibitor, dual tyrosine kinase inhibitor, and PARP inhibitor is promising as demonstrated in the in vitro studies. Approximately 34 patients with breast cancer went through CIRT treatment, as reported in 5 clinical studies. All studies demonstrated promising treatment effects with acceptable and manageable risks. In these studies, a total of 21 patients were reported with post-treatment response assessments, among whom 19 patients (90.48%) reported a response of complete response or partial response. The complete response rate was 66.67%. The time to complete the response ranged from 3 months to 24 months. No adverse events were observed in these studies except for grade 1 acute skin reaction in 14 out of the 21 patients (66.67%). Although the time to respond was longer than expected in some studies, the persistent responses and satisfactory safety profile provided the rationale for further research on this new therapy.</p>","PeriodicalId":36923,"journal":{"name":"International Journal of Particle Therapy","volume":"14 ","pages":"100629"},"PeriodicalIF":2.1000,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11415881/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Particle Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.ijpt.2024.100629","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

To explore the challenges and future of carbon-ion radiation therapy (CIRT) in breast cancer, we summarized the progress of nonclinical and clinical studies on CIRT for breast cancer in this review. A total of 6 nonclinical studies have been reported, which demonstrated a better effect of Carbon-ion irradiation compared with X-ray in breast cancer cell lines (including triple-negative breast cancer and Human Epidermal Growth Factor Receptor 2-negative breast cancer). Combination with Hh inhibitor, dual tyrosine kinase inhibitor, and PARP inhibitor is promising as demonstrated in the in vitro studies. Approximately 34 patients with breast cancer went through CIRT treatment, as reported in 5 clinical studies. All studies demonstrated promising treatment effects with acceptable and manageable risks. In these studies, a total of 21 patients were reported with post-treatment response assessments, among whom 19 patients (90.48%) reported a response of complete response or partial response. The complete response rate was 66.67%. The time to complete the response ranged from 3 months to 24 months. No adverse events were observed in these studies except for grade 1 acute skin reaction in 14 out of the 21 patients (66.67%). Although the time to respond was longer than expected in some studies, the persistent responses and satisfactory safety profile provided the rationale for further research on this new therapy.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
碳-离子放射治疗对乳腺癌的价值。
为了探讨碳离子放射治疗(CIRT)在乳腺癌中的挑战和前景,我们在这篇综述中总结了碳离子放射治疗乳腺癌的非临床和临床研究进展。共有 6 项非临床研究表明,与 X 射线相比,碳离子照射对乳腺癌细胞系(包括三阴性乳腺癌和人表皮生长因子受体 2 阴性乳腺癌)的效果更好。体外研究表明,与 Hh 抑制剂、双重酪氨酸激酶抑制剂和 PARP 抑制剂联合使用很有前景。据 5 项临床研究报告,约有 34 名乳腺癌患者接受了 CIRT 治疗。所有研究都表明,治疗效果良好,风险可接受且可控。在这些研究中,共有 21 名患者进行了治疗后反应评估,其中 19 名患者(90.48%)报告了完全反应或部分反应。完全应答率为 66.67%。完全应答的时间从 3 个月到 24 个月不等。在这些研究中,除了 21 名患者中有 14 名(66.67%)出现 1 级急性皮肤反应外,未观察到其他不良反应。虽然某些研究中出现应答的时间比预期的要长,但持续的应答和令人满意的安全性为进一步研究这种新疗法提供了依据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
International Journal of Particle Therapy
International Journal of Particle Therapy Medicine-Radiology, Nuclear Medicine and Imaging
CiteScore
3.70
自引率
5.90%
发文量
23
审稿时长
20 weeks
期刊最新文献
Impact of COVID-19 Pandemic on Carbon-Ion Radiation Therapy in Japan: A Japanese National Registry Study. The Level of Circulating M-MDSCs as an Indicator for the Therapeutic Outcome of BNCT in End-Stage Malignant Brain Tumor Patients. Vaginal Mucosal Melanoma Cell Activation in Response to Photon or Carbon Ion Irradiation. Navigating a New Frontier: Evaluating Leadless Pacemakers in Proton Therapy. Cardiac Conduction System as an OAR in Radiation Therapy: Doses to SA/AV Nodes and Their Reduction.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1